EORTC Scientific Strategy Meeting 25-26 March 1999

European Journal of Cancer

Volumn 35, Issue 10, 1999, Pages 1423-1430

  Meunier, F ^a   Horiot, J C ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONFERENCE PAPER; EUROPE; HUMAN; LEUKEMIA; MELANOMA; METHODOLOGY; ONCOLOGY; OSTEOSARCOMA; PRIORITY JOURNAL; QUALITY CONTROL;

BELGIUM; CLINICAL TRIALS; HUMANS; INTERPROFESSIONAL RELATIONS; MEDICAL ONCOLOGY; NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF LIFE; SOCIETIES, MEDICAL;

EID: 0032857461     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00184-7     Document Type: Conference Paper

References (40)

1. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995,332, 217-223.
2. Keating S, Suciu S, De Witte T, et al. for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation 1996,17, 993-1001.
3. De Witte T, Suciu S, Selleslag D, et al. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate dose cytosine-arabinoside and interspaced continous infusions of idarubicin: a phase II study (nr. 06901) of the EORTC Leukemia Cooperative Group. Ann Haematol 1996, 72, 119-124.
4. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony stimulating factor (Molgramostin) associated to induction treatment of acute myelogenous leukemia: a randomized trial from EORTC and GIMEMA Leukemia Cooperative Groups. JClin Oncol 1996, 14, 2150-2159.
5. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A study. BMT 1997, 20, 307-315.
6. Keating S, De Witte T, Suciu S, et al. The influence of HLAmatched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukemia Cooperative Group and GIMEMA. Br J Haematol 1998, 102, 1344-1353.
7. Keating S, De Witte T, Suciu S, et al. Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia: an analysis of the AML 8A study of the Leukemia Cooperative Groups of the EORTC and GIMEMA. Eur J Cancer 1999, 35, 1440-1447.
8. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating-factor (GMCSF) during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11. A phase III randomized study of the EORTC-LCG and HOVON Groups. Blood 1997, 90, 29522961.
9. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicine in induction-consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission as well as an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the EORTC-LCG HOVON randomized phase III study AML-9. J Clin Oncol 1998, 16, 872-881.
10. Vegt PDJ, Van Der Meijden APM, Sylvester R, et al. of the European Organization for Research and Treatment of Cancer Genitourinary Group. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911. J Ural 1997, 157, 1246-1249.
11. Pawinski A, Sylvester R, Kurth KG, et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaTl bladder cancer. J Urol 1996, 155, 1934-1941.
12. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998, 33, 144-151.
13. De Voogt HJ, Studer U, Schröder FH, Klijn JG, De Pauw M, Sylvester R. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or longterm (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998, 33, 152-158.
14. Sylvester R, Denis L, De Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998, 33, 134-143.
15. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. NEnglJ Med 1997, 337, 295-300.
16. De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus four cycles of VIP in patients with intermediate-prognosis metastatic testicular non seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1998, 78(6), 828-832.
17. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim (G-CSF) during combination chemotherapy for patients with poor prognosis metastatic testicular germ cell malignancy (a phase III trial of the EORTC GU Group/MRC Testicular Cancer Working Party). 3 Clin Oncol 1998, 16(2), 716-724.
18. Kaye SB, Mead GM, Fossa SD, et al. Intensive inductionsequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998, 16, 692-701.
19. Collette L, Sylvester R, Stenning S, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. J Natl Cancer Inst 1999,91(10), 839-846.
20. Feuer E, Sheinfeld J, Bosl G. Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 1999, 91(10), 816-818.
21. De Mulder PHM, Oosterhof GON, Bouffioux C, Van Oosterom AT, Vermeylen K, Sylvester R on behalf of the EORTC Genitourinary Group. EORTC (30885) randomized phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. BrJ Cancer 1995, 71, 371-375.
22. Van Dongen JA and the EORTC Breast Cancer Cooperative Group. Manual for Clinical Research in Breast Cancer. 3rd edition Almere, Excerpta Medica, 1998, 7-132.
23. Bartelink H, Rubens RD, Van Der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997, 15(1), 207-215.
24. Curran D, Van Dongen JP, Aaronson N, et al. Quality of life of early breast cancer patients treated with mastectomy or breast conserving procedures: results of EORTC trial 10801. Eur J Cancer 1998, 34, 307-314.
25. Aaronson N, Ahmedzai S, Bergman B, et al. QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
26. Payers PM, Weeden S, Curran D on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Reference Values, 3rd edition. Brussels, EORTC manual, 1999.
27. Young T, De Haes JCJM, Curran D, Payers PM, Brandberg Y on behalf of the EORTC Quality of life study group. Guidelines for Assessing Quality of Life in EORTC Clinical Trials, 1st edition. Brussels, EORTC manual, 1999.
28. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T for the EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996, 88(13), 890-899.
29. Forastiere A. Another look at induction chemotherapy for organ preservation in patients with head and neck cancer. J Natl Cancer Inst 1996, 88(13), 855-856.
30. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1998, 15(5), 20402049.
31. Bosset JF, Gignoux M, Triboulet JP, et al. Chemo-radiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 1997, 337, 161167.
32. Bernier J, Horiot JC, Bartelink H, et al. Profile of radiotherapy departments contributing to the EORTC Radiotherapy Cooperative group. Int J Radiation Oncol 1996, 34(4), 953-960.
33. Gallagher M. International quality control/quality assurance. Int J Radiation Oncol 1996, 14(4), 965-967.
34. Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Grit Rev OncollHematol 1995, 20, 193201.
35. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-conaining first-line regimens-an EORTC Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999, 17(1), 150-157.
36. Brasseur F, Rimoldi D, Liénard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63, 375-380.
37. Henz BM, Macher E, Brocker EB, et al. Prognostic value of tuberculin and BCG immunorectivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology 1996, 193, 105-109.
38. Autier PH, Dore JF, Schifflers E, et al. for the EORTC Melanoma Cooperative Group. Melanoma and the use of sunscreens an EORTC case-control study in Germany, Belgium and France. IntJ Cancer 1995, 61, 749-755.
39. Autier P, Dore JF, Lejeune FJ, et al. for the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Cooperative Group. Sun protection in childhood or early adolescence and reduction of melanoma risk in adults: an EORTC case-control study in Germany, Belgium and France.^ EpidBiostat 1996, 1, 51-57.
40. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high risk (1.5 mm thick) limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998, 16, 2906-2912.